Progevera 10 mg® Versus Orgalutran® in Ovarian Stimulation Cycles of Oocyte Donors
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02796105 |
Recruitment Status :
Completed
First Posted : June 10, 2016
Last Update Posted : September 13, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Infertility | Drug: Progevera Drug: Orgalutran | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 232 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Other |
Official Title: | Evaluation of Efficacy and Safety of Medroxiprogesterone Acetate (Progevera 10 mg®) Versus GnRh Antagonist (Orgalutran®) in Ovarian Stimulation Cycles of Oocyte Donors |
Actual Study Start Date : | June 2016 |
Actual Primary Completion Date : | July 2017 |
Actual Study Completion Date : | July 10, 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: Progevera
Progevera 10 mg
|
Drug: Progevera |
Active Comparator: Orgalutran
Orgalutran 0.25 mg
|
Drug: Orgalutran |
- donor ovarian response [ Time Frame: 1 month ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 35 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Oocyte donors included in the oocyte donation program of Clinica EUGIN.
- 1st oocyte donation cycle at Clínica EUGIN.
Exclusion Criteria:
- Polycistic Ovarian syndrome (PCOs).
- Estradiol levels on day 2 of menstrual cycle >70 pg/ml.
- Hormone treatments up to 3 months before the oocyte donation cycle.
- Medical contraindication to the treatments used in the study

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02796105
Spain | |
Clinica Eugin | |
Barcelona, Spain |
Principal Investigator: | Rebeca Begueria, Dr | Clinica Eugin |
Responsible Party: | Fundació Privada Eugin |
ClinicalTrials.gov Identifier: | NCT02796105 |
Other Study ID Numbers: |
BRAKE |
First Posted: | June 10, 2016 Key Record Dates |
Last Update Posted: | September 13, 2017 |
Last Verified: | September 2017 |
Infertility Ganirelix Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs |